GlassScriptPhysician profile
Aparna Brown
NPI 1174570337
$2,818.49
in general payments reported to CMS, 2019-2025
30 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,750 · 2020: $254 · 2021: $39.57 · 2022: $87.72 · 2023: $128 · 2024: $258 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $394.19 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $272.74 | 2019-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $257.57 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $224.35 | 2019-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $222.39 | 2019-2025 | |
| Amgen INC. | $156.45 | 2019-2024 | Evenity |
| Medtronic Minimed, INC. | $152.85 | 2019-2020 | |
| Abbott Laboratories | $148.40 | 2019-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $109.92 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $95.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $89.53 | 2019-2020 | |
| Insulet Corporation | $77.09 | 2019 | |
| Shire North American Group INC | $60.69 | 2019 | |
| Abbvie INC. | $47.91 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $47.18 | 2019 | |
| Mannkind Corporation | $41.05 | 2019-2020 | |
| Amarin Pharma, INC. | $39.94 | 2019 | |
| Sequel Med Tech, LLC | $39.15 | 2025 | Twiist |
| Antares Pharma, INC. | $38.69 | 2019-2024 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $35.57 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.84 | 2019 | |
| Merck Sharp & Dohme LLC | $24.49 | 2019 | |
| Pfizer INC. | $24.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.62 | 2020 | |
| Beta Bionics, INC. | $16.04 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $15.77 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $15.33 | 2019 | |
| Sandoz INC. | $14.09 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aparna Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.